Wireless power transfer(WPT)offers significant advantages,particularly due to its flexibility,enabling diverse applications.However,conventional single-transmitter,single-receiver systems are limited by their sensitiv...Wireless power transfer(WPT)offers significant advantages,particularly due to its flexibility,enabling diverse applications.However,conventional single-transmitter,single-receiver systems are limited by their sensitivity to lateral disturbances,frequency instability,and strict distance constraints.Recently,multiple-transmitter,single-receiver(MTSR)systems have gained attention for their potential to enhance system flexibility and reliability.In this work,we propose an efficient second-order anti-parity‒time(anti-PT)symmetry by introducing two transmitters that simultaneously exchange energy with the external channel.This concept is further extended to third-order anti-PT symmetry for efficient WPT in MTSR systems.By leveraging interference between shared sources,we construct virtual coupling instead of relying on traditional resistive losses.Remarkably,our system maintains frequency stability,broad bandwidth,and robust high-efficiency power transfer even when the resonant frequencies of the transmitter and receiver coils are mismatched.This innovation challenges conventional understanding and opens new directions for WPT technology.展开更多
We investigated the Talbot effect in an anti-parity-time(PT)symmetric synthetic photonic lattice composed of two coupled fiber loops.We calculated the band structures and found that with an increase in the gain-loss p...We investigated the Talbot effect in an anti-parity-time(PT)symmetric synthetic photonic lattice composed of two coupled fiber loops.We calculated the band structures and found that with an increase in the gain-loss parameter,the band transitions from a real spectrum to a complex spectrum.We study the influence of phase in the Hermitian operator on the Talbot effect,and the Talbot effect disappears when the period of the input field is N>8.Further study shows that the variation of Talbot distance can also be modulated by non-Hermitian coefficients of gain and loss.This work may find significant applications in pulse repetition-rate multiplication,temporal invisibility,and tunable intensity amplifiers.展开更多
目的通过筛选真实世界中非瓣膜性房颤(NVAF)合并肾功能不全[15<肌酐清除率(CL_(cr))≤60 mL·min^(-1)]患者联用利伐沙班致出血风险增加的药代动力学相互作用(PK-DDI)药品,以促进临床合理用药。方法通过检索文献(PubMed、Web of ...目的通过筛选真实世界中非瓣膜性房颤(NVAF)合并肾功能不全[15<肌酐清除率(CL_(cr))≤60 mL·min^(-1)]患者联用利伐沙班致出血风险增加的药代动力学相互作用(PK-DDI)药品,以促进临床合理用药。方法通过检索文献(PubMed、Web of Science、中国知网、万方数据、维普网)、说明书、2021年欧洲心律协会指南、Lexicomp数据库总结利伐沙班PK-DDI目录;采用回顾性队列研究,收集2022年11月1日至2023年10月31日在首都医科大学宣武医院住院并服用利伐沙班的NVAF合并肾功能不全患者,根据是否使用利伐沙班PK-DDI药品分为PK-DDI组和非PK-DDI组。其中PK-DDI药品限定为P-gp和/或CYP3A4抑制剂,随访3个月,比较2组患者有效性和安全性结局。结果共计22类141种药品,根据是否需调整剂量分类,需要禁用、慎用药品65种和无需调整剂量药品76种。研究共纳入患者143例,PK-DDI组出血发生率高于非PK-DDI组(P<0.05),PK-DDI组与非PK-DDI组的缺血性卒中发生率差异无统计学意义(P>0.05)。PK-DDI组主要的出血性事件为临床相关非大出血(8例,61.5%),用药后30 d内出血发生率为38.7%,涉及药品包含胺碘酮、银杏叶提取物、氟康唑、伏立康唑、奥希替尼。结论利伐沙班PK-DDI涉及多种药品,主要靶点为P-gp和CYP3A4。肾功能不全患者服用利伐沙班时,联用P-gp和/或CYP3A4抑制剂增加出血风险。利伐沙班应避免与银杏叶提取物、伏立康唑联用。利伐沙班与胺碘酮、氟康唑、奥希替尼联用需严密监测,如凝血酶原时间、抗凝血(Xa)因子水平或利伐沙班血药浓度。展开更多
基金supported by the National Key R&D Program of China(Nos.2021YFA1400602 and 2023YFA1407600)the National Natural Science Foundation of China(Nos.12374294 and 52477014)the Chenguang Program of Shanghai(No.21CGA22).
文摘Wireless power transfer(WPT)offers significant advantages,particularly due to its flexibility,enabling diverse applications.However,conventional single-transmitter,single-receiver systems are limited by their sensitivity to lateral disturbances,frequency instability,and strict distance constraints.Recently,multiple-transmitter,single-receiver(MTSR)systems have gained attention for their potential to enhance system flexibility and reliability.In this work,we propose an efficient second-order anti-parity‒time(anti-PT)symmetry by introducing two transmitters that simultaneously exchange energy with the external channel.This concept is further extended to third-order anti-PT symmetry for efficient WPT in MTSR systems.By leveraging interference between shared sources,we construct virtual coupling instead of relying on traditional resistive losses.Remarkably,our system maintains frequency stability,broad bandwidth,and robust high-efficiency power transfer even when the resonant frequencies of the transmitter and receiver coils are mismatched.This innovation challenges conventional understanding and opens new directions for WPT technology.
基金supported by the National Key Research and Development Program of China(Nos.2022YFA1404800 and 2019YFA0705000)the National Natural Science Foundation of China(Nos.12104272,12274270,91950104,12192254,92250304,and 11974218)the Local Science and Technology Development Project of the Central Government(No.YDZX20203700001766)。
文摘We investigated the Talbot effect in an anti-parity-time(PT)symmetric synthetic photonic lattice composed of two coupled fiber loops.We calculated the band structures and found that with an increase in the gain-loss parameter,the band transitions from a real spectrum to a complex spectrum.We study the influence of phase in the Hermitian operator on the Talbot effect,and the Talbot effect disappears when the period of the input field is N>8.Further study shows that the variation of Talbot distance can also be modulated by non-Hermitian coefficients of gain and loss.This work may find significant applications in pulse repetition-rate multiplication,temporal invisibility,and tunable intensity amplifiers.
文摘目的通过筛选真实世界中非瓣膜性房颤(NVAF)合并肾功能不全[15<肌酐清除率(CL_(cr))≤60 mL·min^(-1)]患者联用利伐沙班致出血风险增加的药代动力学相互作用(PK-DDI)药品,以促进临床合理用药。方法通过检索文献(PubMed、Web of Science、中国知网、万方数据、维普网)、说明书、2021年欧洲心律协会指南、Lexicomp数据库总结利伐沙班PK-DDI目录;采用回顾性队列研究,收集2022年11月1日至2023年10月31日在首都医科大学宣武医院住院并服用利伐沙班的NVAF合并肾功能不全患者,根据是否使用利伐沙班PK-DDI药品分为PK-DDI组和非PK-DDI组。其中PK-DDI药品限定为P-gp和/或CYP3A4抑制剂,随访3个月,比较2组患者有效性和安全性结局。结果共计22类141种药品,根据是否需调整剂量分类,需要禁用、慎用药品65种和无需调整剂量药品76种。研究共纳入患者143例,PK-DDI组出血发生率高于非PK-DDI组(P<0.05),PK-DDI组与非PK-DDI组的缺血性卒中发生率差异无统计学意义(P>0.05)。PK-DDI组主要的出血性事件为临床相关非大出血(8例,61.5%),用药后30 d内出血发生率为38.7%,涉及药品包含胺碘酮、银杏叶提取物、氟康唑、伏立康唑、奥希替尼。结论利伐沙班PK-DDI涉及多种药品,主要靶点为P-gp和CYP3A4。肾功能不全患者服用利伐沙班时,联用P-gp和/或CYP3A4抑制剂增加出血风险。利伐沙班应避免与银杏叶提取物、伏立康唑联用。利伐沙班与胺碘酮、氟康唑、奥希替尼联用需严密监测,如凝血酶原时间、抗凝血(Xa)因子水平或利伐沙班血药浓度。
基金the National Natural Science Foundation of China (20471027) for the financialaid to this researchChina Postdoctoral Research Fund (1107040063)supported by Nanjing University Graduate Students Innovation Funding(2006CL09)~~
